MDGN Share Price

Open 5.41 Change Price %
High 5.64 1 Day 0.17 3.15
Low 5.34 1 Week 0.00 0.00
Close 5.57 1 Month 0.00 0.00
Volume 141056 1 Year 1.47 35.85
52 Week High 6.60
52 Week Low 3.60
MDGN Important Levels
Resistance 2 5.85
Resistance 1 5.73
Pivot 5.52
Support 1 5.41
Support 2 5.29
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
NAK 1.55 -6.06%
NAK 1.55 -6.06%
NGD 2.99 -1.64%
NGD 2.99 -1.64%
RBY 0.03 -70.00%
PBTH 8.23 0.37%
NSU 2.72 -7.48%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
CHGS 0.00 -100.00%
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
More..

Medgenics, Inc. (AMEX: MDGN)

MDGN Technical Analysis 4
As on 15th Dec 2016 MDGN Share Price closed @ 5.57 and we RECOMMEND Buy for LONG-TERM with Stoploss of 5.08 & Strong Buy for SHORT-TERM with Stoploss of 5.23 we also expect STOCK to react on Following IMPORTANT LEVELS.
MDGN Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
MDGN Other Details
Segment EQ
Market Capital 109150520.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.medgenics.com
MDGN Address
MDGN
435 Devon Park Drive
Building 700
Wayne, PA 19087
United States
Phone: 610-254-4201
MDGN Latest News
Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc.   PR Newswire (press release)   - 15th Dec 16
Medgenics, Inc. to Begin Trading on NASDAQ Global Market   Marketwired (press release)   - 11th Oct 16
Why Medgenics Inc.'s Shares Are Down Big Today   Motley Fool   - 21st Jun 16
Big Data Biotech: Medgenics Inc (NYSEMKT:MDGN) and Kura Oncology Inc (NASDAQ:KURA)   Market Exclusive   - 20th Jun 16
Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD   Marketwired (press release)   - 06th Jun 16
Medgenics Hires Eric Phillips, MPH, ScD as Vice President of Regulatory Affairs   Marketwired (press release)   - 20th Apr 16
Medgenics Announces Key Appointments   GlobeNewswire (press release)   - 13th Oct 15
Medgenics Acquires Phase 2-Ready CNS Program: NFC-1   GlobeNewswire (press release)   - 09th Sep 15
Medgenics Announces Appointment of Barbara Duncan to Board of Directors   GlobeNewswire (press release)   - 10th Jun 15
Medgenics Announces the Appointment of Scott Applebaum as Chief Legal Officer   GlobeNewswire (press release)   - 10th Sep 14
Interactive Technical Analysis Chart Medgenics, Inc. ( MDGN AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Medgenics, Inc.
MDGN Business Profile
Medgenics, Inc., a medical technology and therapeutics company, is engaged in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops and commercializes Biopump platform technology that converts a piece of the patient’s own dermal skin tissue into a protein- and/or peptide-producing ‘Biopump’ to produce and deliver therapeutic proteins and/or peptides, and—when implanted under the patient’s skin—has the potential to deliver various months of protein/peptide therapy. Its product candidates include EPODURE Biopump, which is in Phase I/II clinical trials for the treatment of anemia in CKD and renal failure; and HEMODURE Biopump, which is under pre-clinical studies and produces Factor VIII for the treatment of patients with hemophilia. The company also develops INFRADURE Biopump that produces interferon-alpha for the treatment of patients with hepatitis C. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.